Potential for Larger Gene Panels to Increase the Number of Molecularly Matched Therapies in Patients with Advanced Solid Tumours By Ogkologos - April 22, 2025 700 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ProfiLER-02 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Adding Palbociclib to Maintenance Anti-HER2 and Endocrine Therapies Improves PFS Over... February 5, 2026 How does processed and red meat cause cancer and how much... March 17, 2021 EMA Recommends Extension of Indications for Dabrafenib and Trametinib May 6, 2026 A Single Colonoscopy Reduces CRC Risk, but Not CRC Mortality May 11, 2026 Load more HOT NEWS 38% of Recurrent Breast Cancers Have a Different HER2 Status than... Lisocabtagene Maraleucel in Relapsed or Refractory Large B-cell Lymphomas Study Finds Accelerated Partial-Breast Radiation Just as Effective as Whole Breast... Wistful Facebook Comment Sends Volunteers Flocking To Help MS Patient Fulfill...
